These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 19565942)

  • 21. [HIV infection, antiretroviral therapy, and endothelium].
    Hürlimann D; Weber R; Enseleit F; Lüscher TF
    Herz; 2005 Sep; 30(6):472-80. PubMed ID: 16170677
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prevalence of highly active antiretroviral therapy associated metabolic abnormalities and lipodystrophy in HIV infected patients.
    Feleke Y; Fekade D; Mezegebu Y
    Ethiop Med J; 2012 Jul; 50(3):221-30. PubMed ID: 23409405
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Hepatotoxicity with antiretroviral therapy. The liver is affected as well].
    MMW Fortschr Med; 2002 Apr; 144 Suppl 1():14-5. PubMed ID: 12043064
    [No Abstract]   [Full Text] [Related]  

  • 24. Antiretroviral therapy based on protease inhibitors as a protective factor against liver fibrosis progression in patients with chronic hepatitis C.
    Macías J; Mira JA; López-Cortés LF; Santos I; Girón-González JA; González-Serrano M; Merino D; Hernández-Quero J; Rivero A; Merchante N; Trastoy M; Carrillo-Gómez R; Arizcorreta-Yarza A; Gómez-Mateos J; Pineda JA
    Antivir Ther; 2006; 11(7):839-46. PubMed ID: 17302246
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Acute liver enzyme elevations in HIV-1-infected patients.
    Livry C; Binquet C; Sgro C; Froidure M; Duong M; Buisson M; Grappin M; Quantin C; Portier H; Chavanet P; Piroth L
    HIV Clin Trials; 2003; 4(6):400-10. PubMed ID: 14628283
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hyperlactatemia and in utero exposure to antiretrovirals: is the control group the clue?
    Soler-Palacín P; Martín-Nalda A; Martínez-Gómez X; Melendo S; Riudor E; Arranz JA; Espiau M; Figueras C
    AIDS Res Hum Retroviruses; 2012 Aug; 28(8):752-8. PubMed ID: 22010980
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Liver triglyceride content in HIV-1-infected patients on combination antiretroviral therapy studied with 1H-MR spectroscopy.
    Moreno-Torres A; Domingo P; Pujol J; Blanco-Vaca F; Arroyo JA; Sambeat MA
    Antivir Ther; 2007; 12(2):195-203. PubMed ID: 17503662
    [TBL] [Abstract][Full Text] [Related]  

  • 28. HIV infection, antiretroviral therapy, and hepatic function. Emerging epidemiological, pathogenetic, and clinical issues, and their consequences on disease management.
    Manfredi R
    AIDS; 2003 Oct; 17(15):2253-6. PubMed ID: 14523283
    [No Abstract]   [Full Text] [Related]  

  • 29. Metabolic and hepatobiliary side effects of antiretroviral therapy (ART).
    Lugassy DM; Farmer BM; Nelson LS
    Emerg Med Clin North Am; 2010 May; 28(2):409-19, Table of Contents. PubMed ID: 20413022
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Liver Disease in Human Immunodeficiency Virus Infection.
    Oikonomou KG; Tsai E; Sarpel D; Dieterich DT
    Clin Liver Dis; 2019 May; 23(2):309-329. PubMed ID: 30947879
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Complications of human immunodeficiency virus therapy.
    Hayes EV; McGann KA
    Pediatr Infect Dis J; 2004 Sep; 23(9):873-4. PubMed ID: 15361730
    [No Abstract]   [Full Text] [Related]  

  • 32. Hepatotoxicity of antiretroviral therapy.
    Kontorinis N; Dieterich D
    AIDS Rev; 2003; 5(1):36-43. PubMed ID: 12875106
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nodular regenerative hyperplasia: a new serious antiretroviral drugs side effect?
    Sandrine PF; Sylvie A; André E; Abdoulaye D; Bernard L; André C
    AIDS; 2007 Jul; 21(11):1498-9. PubMed ID: 17589205
    [No Abstract]   [Full Text] [Related]  

  • 34. Hepatotoxicity of Contemporary Antiretroviral Drugs: A Review and Evaluation of Published Clinical Data.
    Otto AO; Rivera CG; Zeuli JD; Temesgen Z
    Cells; 2021 May; 10(5):. PubMed ID: 34065305
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Spectrum of adverse events after generic HAART in southern Indian HIV-infected patients.
    Kumarasamy N; Venkatesh KK; Cecelia AJ; Devaleenal B; Lai AR; Saghayam S; Balakrishnan P; Yepthomi T; Poongulali S; Flanigan TP; Solomon S; Mayer KH
    AIDS Patient Care STDS; 2008 Apr; 22(4):337-44. PubMed ID: 18422462
    [TBL] [Abstract][Full Text] [Related]  

  • 36. HIV-related liver disease: ARV drugs, coinfection, and other risk factors.
    Puoti M; Nasta P; Gatti F; Matti A; Prestini K; Biasi L; Carosi G
    J Int Assoc Physicians AIDS Care (Chic); 2009; 8(1):30-42. PubMed ID: 19211929
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Subclinical contractility impairment in HIV-infected patients: dependence on the class of antiretroviral drugs.
    Mercuro G; Cadeddu C; Nocco S; Deidda M; Mercuro S; Piano P; Ortu F; Manconi PE
    Int J Cardiol; 2013 Sep; 168(2):1538-9. PubMed ID: 23287696
    [No Abstract]   [Full Text] [Related]  

  • 38. Challenges of developing R5 inhibitors in antiretroviral naive HIV-infected patients.
    Deeks SG
    Lancet; 2006 Mar; 367(9512):711-3. PubMed ID: 16517257
    [No Abstract]   [Full Text] [Related]  

  • 39. The influence of HIV infection and antiretroviral therapy on the mitochondrial membrane potential of peripheral mononuclear cells.
    Sternfeld T; Schmid M; Tischleder A; Mudra S; Schlamp A; Kost BP; Gruber R; Youle M; Bogner JR; Goebel FD
    Antivir Ther; 2007; 12(5):769-78. PubMed ID: 17713160
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [HAART and pregnancy. Nelfinavir superiority in hepatotoxicity].
    MMW Fortschr Med; 2004 Apr; 146 Spec No 1():45. PubMed ID: 15373048
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.